With regard to future research directions, investigating larger sample sizes across multiple centers is crucial, to more accurately assess the safety of omitting RNI in both ER-positive and HER2-overexpressing breast cancer patients with 1-3 positive lymph nodes who are receiving targeted therapy. Here, ERBB2 is linked to breast carcinoma.